Hem/Onc Roundup: Pharma CEO Talks Cellular Therapy, and More

Each week on DocWire News, editors bring you the latest news and research in hematology and oncology. In case you missed it, here are this week’s top headlines.

The highlights:

This Week on DocWire…

Pharma CEO Discusses Cellular Therapy for Cancers

Editors spoke with Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, Inc., a company developing innovative therapies that target various phases of cell control for treating advanced cancers. Mr. Rombotis discussed the strides his company is making in developing and testing targeted therapies that may actually drive cancer cells to “self-destruct.”

“Essentially, when a cancer cell has progressed to the point that if the generated its code contains mistakes that can be communicated to daughter cells, many of the own circulatory mechanisms of the body are dysfunctional or absent,” he explained. “By inhibiting both CDK2 and CDK9, we can reinstitute these mechanisms, or ‘programed suicide,’ and engage those anti-cancer mechanisms you want to stop working and induce the cancer cell to commit suicide.”

Watch the full interview to learn more.

Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced Cancer

Can PCPs Help Improve Low Screening Rates?

Primary care providers (PCP) play a critical role in cancer diagnosis, according to a new study from researchers at the University of Michigan Rogel Cancer Center. The findings showed that the older women who reported feeling included in healthcare decisions with their PCP were more likely to be up to date on both colorectal and cervical cancer screenings.

When the researchers compared women who completed both screenings compared to those who had only one screening, they found that communication about health decisions with a PCP was still associated with being up to date on both screenings compared to one.

“This creates a hypothesis that comprehensive cancer screening may best be accomplished through a PCP-patient relationship and not through targeted single cancer site screenings,” said coauthor Diane M. Harper, MD, MPH.

Primary Care Providers Play Important Role in Cancer Screening Uptake

Improving Cancer Screening in Patients with Schizophrenia

Patients with schizophrenia can and should participate in cancer screening to the same extent as the general population, with assistance, according to a study published in Acta Psychiatrica Scandinavica. In this first-of-its-kind study, researchers conducted a randomized trial to assess the benefits of interventions for early cancer screening in patients with schizophrenia.

“The dissemination of this intervention into routine clinical practice may help bridge the gap between early detection of cancer and mortality across people with schizophrenia and the general population,” said the study authors.

Intervention is Needed to Increase Screening for Early Cancer Screening in Patients with Mental Illness

HIIT Regimen Shows Benefit for Men at Risk of Prostate Cancer

Finally, for men with low-risk to favorable intermediate-risk prostate cancer undergoing active surveillance, high-intensity interval training (HIIT) was found to be beneficial. A new study found that patients who underwent HIIT exercises three times per week experienced decreased PSA level and velocity and prostate cancer cell line LNCaP growth compared to standard care patients.

The HIIT group experienced decreased PSA level (−1.1 µg/L), PSA velocity (−1.3 µg/L/year), and prostate cancer cell line LNCaP growth (−0.13 optical density unit) compared with the usual care group.

“Demonstration that HIIT alone, without dietary changes, resulted in improved cardiorespiratory fitness and biochemical parameters in men with localized prostate cancer on active surveillance and growth inhibition at the cellular level is novel and noteworthy,” write the authors of an accompanying editorial.

High-Intensity Interval Training Beneficial in Prostate Cancer